Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB

Dmitry A Butov, Yuri N Pashkov, Anna L Stepanenko, Aleksandra I Choporova, Tanya S Butova, Dendev Batdelger, Vichai Jirathitikal, Aldar S Bourinbaiar, Svetlana I Zaitzeva, Dmitry A Butov, Yuri N Pashkov, Anna L Stepanenko, Aleksandra I Choporova, Tanya S Butova, Dendev Batdelger, Vichai Jirathitikal, Aldar S Bourinbaiar, Svetlana I Zaitzeva

Abstract

Placebo-controlled, randomized, phase 2b trial was conducted in 34 adults comprising 18 first-diagnosed (52.9%), 6 relapsed (17.6%), and 10 MDR-TB (29.4%) cases to investigate the safety and efficacy of an oral immune adjunct (V5). The immunotherapy (N = 24) and placebo (N = 10) arms received once-daily tablet of V5 or placebo for one month in addition to conventional anti-TB therapy (ATT) administered under directly observed therapy (DOT).The enlarged liver, total bilirubin, erythrocyte sedimentation rate, lymphocyte and leukocyte counts improved significantly in V5 recipients (P = 0.002; 0.03; 8.3E-007; 2.8E-005; and 0.002) but remained statistically unchanged in the placebo group (P = 0.68; 0.96; 0.61; 0.91; and 0.43 respectively). The changes in hemoglobin and ALT levels in both treatment arms were not significant. The body weight increased in all V5-treated patients by an average 3.5 ± 1.8 kg (P = 2.3E-009), while 6 out of 10 patients on placebo gained mean 0.9 ± 0.9 kg (P = 0.01). Mycobacterial clearance in sputum smears was observed in 78.3% and 0% of patients on V5 and placebo (P = 0.009). The conversion rate in V5-receiving subjects with MDR-TB (87.5%) seemed to be higher than in first-diagnosed TB (61.5%) but the difference was not significant (P = 0.62). Scoring of sputum bacillary load (range 3-0) at baseline and post-treatment revealed score reduction in 23 out of 24 (95.8%) V5 recipients (from mean/median 2.2/3 to 0.3/0; P = 6E-010) but only in 1 out of 10 (10%) patients on placebo (1.9/1.5 vs. 1.8/1; P = 0.34). No adverse effects or TB reactivation were seen at any time during follow-up. V5 is safe as an immune adjunct to chemotherapeutic management of TB and can shorten substantially the duration of treatment.

Figures

Figure 1
Figure 1
The proportion of ATT-treated patients in V5 and placebo arms who have benefited from the therapy according to the measured endpoints.
Figure 2
Figure 2
The percentage of sputum smear-negative patients in placebo and V5 arms administered in combination with TB drugs for one month. The upper paired bar shows conversion rate in placebo recipients (0%) in comparison to V5 recipients (78.3%) in a total number of enrolled patients (N = 34). Lower paired bars show conversion rates among first-diagnosed TB (1stDx); relapsed TB (RTB); and multidrug-resistant TB (MDR) respectively.

References

    1. Feshchenko YuI, Melnyk VM, Novozhilova IO, Lyrnyk SV. The mortality of patients with tuberculosis: structure, dynamics and peculiarities in epidemic period. Ukr Pulmonol J. 2009;3:5–9.
    1. Nikolayevskyy VV, Brown TJ, Bazhora YI, Asmolov AA, Balabanova YM, Drobniewski FA. Molecular epidemiology and prevalence of mutations conferring rifampicin and isoniazid resistance in Mycobacterium tuberculosis strains from the southern Ukraine. Clin Microbiol Infect. 2007;13:129–138. doi: 10.1111/j.1469-0691.2006.01583.x.
    1. Atun R, Olynik I. Resistance to implementing policy change: the case of Ukraine. Bulletin of World Health Organization. 2008;86:147–154.
    1. Batdelger D, Dandii D, Jirathitikal V, Bourinbaiar AS. Open label trial of therapeutic hepatitis B vaccine V-5 Immunitor (V5) delivered by oral route. Lett Drug Design Discovery. 2007;4:540–544. doi: 10.2174/157018007782794545.
    1. Batdelger D, Dandii D, Jirathitikal V, Bourinbaiar AS. Open label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C. Vaccine. 2008;26:2733–2737. doi: 10.1016/j.vaccine.2008.03.021.
    1. Batdelger D, Dandii D, Dahgwahdorj Ya, Erdenetsogt E, Oyunbileg J, Tsend N, Bayarmagnai B, Jirathitikal V, Bourinbaiar AS. Clinical experience with therapeutic vaccines designed for patients with hepatitis. Curr Pharm Design. 2009;15:1159–1171. doi: 10.2174/138161209787846793.
    1. Arjanova OV, Prihoda ND, Yurchenko LV, Sokolenko NI, Frolov VM, Tarakanovskaya MG, Jirathitikal V, Bourinbaiar AS. Phase 2 trial of V-5 Immunitor (V5) in patients with chronic hepatitis C co-infected with HIV and Mycobacterium tuberculosis. J Vaccin Vaccinat. 2010;1:103.
    1. Arjanova OV, Prihoda ND, Yurchenko LV, Sokolenko NI, Frolov VM, Tarakanovskaya MG, Batdelger D, Jirathitikal V, Bourinbaiar AS. Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV co-infected TB. Immunotherapy. in press .
    1. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 1957;28:56–63.
    1. Ostrovskiĭ VK, Asanov BM, Iangolenko DV. Some blood indices and the leukocytic index of intoxication in tuberculosis, pneumonias, abscesses, and cancer of the lung. Probl Tuberk Bolezn Legk. 2005;3:43–46.
    1. Zaitzeva SI, Matveeva SL, Gerasimova TG, Pashkov YN, Butov DA, Pylypchuk VS, Frolov VM, Kutsyna GA. Treatment of cavitary and infiltrating pulmonary tuberculosis with and without the immunomodulator Dzherelo. Clin Microbiol Infect. 2009;15:1154–1162. doi: 10.1111/j.1469-0691.2009.02760.x.
    1. Veenstra H, Baumann R, Carroll NM, Lukey PT, Kidd M, Beyers N, Bolliger CT, van Helden PD, Walzl G. Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders. Clin Exp Immunol. 2006;145:252–260. doi: 10.1111/j.1365-2249.2006.03144.x.
    1. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR. ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935–952. doi: 10.1164/rccm.200510-1666ST.
    1. Vasantha M, Gopi PG, Subramani R. Weight gain in patients with tuberculosis treated under directly observed treatment short-course (DOTS) Indian J Tuberc. 2009;56:5–9.
    1. Yew WW, Leung CC. Prognostic significance of early weight gain in underweight patients with tuberculosis. Am J Respir Crit Care Med. 2006;174:236–237. doi: 10.1164/rccm.200605-669ED.
    1. Majumdar A, Kamble PD, Harinath BC. Detection of circulating free and immune-complexed antigen in pulmonary tuberculosis using cocktail of antibodies to Mycobacterium tuberculosis excretory secretory antigens by peroxidase enzyme immunoassay. Indian J Tuberc. 2010;57:67–74.
    1. Vilaplana C, Montané E, Pinto S, Barriocanal AM, Domenech G, Torres F, Cardona PJ, Costa J. Double-blind, randomized, placebo-controlled Phase I clinical trial of the therapeutical antituberculous vaccine RUTI. Vaccine. 2010;28:1106–1116. doi: 10.1016/j.vaccine.2009.09.134.
    1. Stanford J, Stanford C, Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front Biosci. 2004;9:1701–1719. doi: 10.2741/1292.
    1. Zhao G-R, Feng D-H. A systematic review of inactivated Mycobacterium phlei injection for adjunctive treatment of drug resistant pulmonary tuberculosis. Pharm J Chin PLA. 2009;25:361–364.
    1. Nyasulu PS. Role of adjunctive Mycobacterium w immunotherapy for tuberculosis. J Exp Clin Med. 2010;2:123–129.
    1. Svistunova AS, Pinegin BV, Selitskaia RP, Arshinova SS, Klimova EG, Andronova TM, Batyrov FA, Simonova AV. The use of immunomodulator likopid in the combined treatment pulmonary tuberculosis. Probl Tuberk. 2002;3:21–25.
    1. Lei JP, Xiong GL, Hu QF, Li Y, Zong PL, Tu SH, Tu RY. Immunotherapeutic efficacy of BCG vaccine in pulmonary tuberculosis and its preventive effect on multidrug-resistant tuberculosis. Zhonghua Yu Fang Yi Xue Za Zhi. 2008;42:86–89.
    1. Kaufmann SH. Is the development of a new tuberculosis vaccine possible? Nat Med. 2000;6:955–960. doi: 10.1038/79631.
    1. Kato S, Tokunaga O, Yoshiyama T. Analysis of Koch's phenomenon by BCG vaccination with the multi-puncture method in Japan. Kekkaku. 2010;85:782–785.
    1. Repique CJ, Li A, Collins FM, Morris SL. DNA Immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge. Infect Immun. 2002;70:3318–3323. doi: 10.1128/IAI.70.7.3318-3323.2002.
    1. Moreira AL, Tsenova L, Aman MH, Bekker L-G, Freeman S, Mangaliso B, Schröder U, Jagirdar J, Rom WN, Tovey MG, Freedman VH, Kaplan G. Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice. Infect Immun. 2002;70:2100–2107. doi: 10.1128/IAI.70.4.2100-2107.2002.
    1. Basaraba RJ, Izzo AA, Brandt L, Orme IM. Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations. Vaccine. 2006;24:280–286. doi: 10.1016/j.vaccine.2005.07.103.
    1. Radaeva TV, Nikonenko BV, Kapina MA, Mishchenko VV, Apt AS. Experimental approaches to designing vaccines against tuberculous infection reactivation. Probl Tuberk Bolezn Legk. 2006;5:45–48.
    1. Cruz A, Fraga AG, Fountain JJ, Rangel-Moreno J, Torrado E, Saraiva M, Pereira DR, Randall TD, Pedrosa J, Cooper AM, Castro AG. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med. 2010;207:1609–1616. doi: 10.1084/jem.20100265.
    1. Derrick SC, Perera LP, Dheenadhayalan V, Yang A, Kolibab K, Morris SL. The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis. Vaccine. 2008;26:6092–6098. doi: 10.1016/j.vaccine.2008.09.011.
    1. Roth AE, Benn CS, Ravn H, Rodrigues A, Lisse IM, Yazdanbakhsh M, Whittle H, Aaby P. Effect of revaccination with BCG in early childhood on mortality: randomised trial in Guinea-Bissau. BMJ. 2010;340:c671. doi: 10.1136/bmj.c671.
    1. Silin DS, Lyubomska OV, Jirathitikal V, Bourinbaiar AS. Oral vaccination: where we are? Expert Opin Drug Deliv. 2007;4:323–340. doi: 10.1517/17425247.4.4.323.
    1. Zaitzeva SI, Matveeva SL, Gerasimova TG, Pashkov YuN, Butov DA, Pylypchuk VS, Frolov VM, Kutsyna GA. Efficacy and safety of phytoconcentrate Dzherelo (Immunoxel) in treatment of patients with multi-drug resistant TB (MDR-TB) in comparison to standard chemotherapy. Res J Med Sci. 2009;3:36–41.
    1. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA. Advances in immunotherapy for tuberculosis treatment. Clin Chest Med. 2009;30:769–782. doi: 10.1016/j.ccm.2009.08.009.
    1. Thaiss CA, Kaufmann SH. Toward novel vaccines against tuberculosis: current hopes and obstacles. Yale J Biol Med. 2010;83:209–215.
    1. Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y. The immunology of tuberculosis: from bench to bedside. Respirology. 2010;15:433–450. doi: 10.1111/j.1440-1843.2010.01739.x.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅